IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR, RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1, ERBB1, HER1, HER-1, ERBB)), MONOCLONAL ANTIBODY CONJUGATED TO THE PYRROLOBENZODIAZEPINE (PDB) DIMER SGD-1882GAMMA1 HEAVY CHAIN (1-446) (VH (HOMO SAPIENS IGHV4-30-4*01 (81.4%)-(IGHD)-IGHJ4*01 (92.9%)) (9.7.9) (1-116)-HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1 (CH1 R120>K (213) (117-214), HINGE (215-229), CH2 S3>C (238) (230-339), CH3 E12 (355), M 14 (357) (340-444), CHS (445-446)) (117-446)), (219-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (V-KAPPA (MUS MUSCULUS IGKV14-100*01 (86.3%)-IGKJ1*01 (100%)/HOMO SAPIENS IGKV1-12*01 (74.7%)-IGKJ4*01 (90.9%)) (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214'))DIMER (225-225'':228-228'')-BISDISULFIDECONJUGATED, ON TWO SITE-SPECIFIC DRUG ATTACHMENT ENGINEERED CYSTEINES (C238, C238''), TO PYRROLOBENZODIAZEPINE (PDB) DIMERS SGD-1882, VIA A CATHEPSIN-CLEAVABLE MALEIMIDOCAPROYLVALINE-ALANINE (MC-VAL-ALA) TYPE LINKER
Advanced Solid Tumors Cancer
AbbVieantibody_drug_conjugatePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Advanced Solid Tumors Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Budigalimab AbbVie | Phase 1 | CCC |
MAB HUMANIZED (IGG1) ANTI P43489 (TNR4_HUMAN) (ABBV368) AbbVie | Phase 1 | CCC |
Ndi-219216 Nimbus Wadjet, Inc. | Phase 1/2 | CC |
gfh375 Genfleet Therapeutics (Shanghai) Inc. | Phase 1/2 | CC |
Tilsotolimod AbbVie | Phase 1 | CC |
View all 20 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →